大和发表报告指，国药控股(01099.HK) 上半年业绩略逊预期，维持“持有”评级。目标价由18元降至17元。报告指，国药上半年总收入按年下跌1.1%至2,828亿元人民币(下同)，净利润按年下跌1.8%至34亿元；两者均低于该行预测及市场预期。期间，零售收入持续保持良好成长势头，其中药品分销收入下降，而医疗器材分销收入则基本保持稳定。大和认为，维持稳定的传统分销业务并拓展创新服务，是国药推动未来...
Source Link大和发表报告指，国药控股(01099.HK) 上半年业绩略逊预期，维持“持有”评级。目标价由18元降至17元。报告指，国药上半年总收入按年下跌1.1%至2,828亿元人民币(下同)，净利润按年下跌1.8%至34亿元；两者均低于该行预测及市场预期。期间，零售收入持续保持良好成长势头，其中药品分销收入下降，而医疗器材分销收入则基本保持稳定。大和认为，维持稳定的传统分销业务并拓展创新服务，是国药推动未来...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.